Photodynamic therapy may be useful in debulking cutaneous lymphoma prior to radiotherapy

Clinical and Experimental Dermatology

Volumn 29, Issue 1, 2004, Pages 42-45

  Umegaki, N ^a   Moritsugu, R ^a   Katoh, S ^a   Harada, K ^a   Nakano, H ^a,b   Tamai, K ^a   Hanada, K ^a   Tanaka, M ^b  

^a Department of Dermatology ^*  (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID;

AGED; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIMODALITY CANCER THERAPY; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; SKIN LYMPHOMA; TUMOR VOLUME;

ADMINISTRATION, TOPICAL; AGED; AMINOLEVULINIC ACID; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOMA, LARGE-CELL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SCALP; SKIN NEOPLASMS;

EID: 0842287392     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2004.01448.x     Document Type: Article

References (11)

1. Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol 2000; 42: 389-413.
2. Wolf P, Fink-Puches R, Cerroni L, Kerl H. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1994; 31: 678-80.
3. Markham T, Sheahan K, Collins P. Topical 5-aminoleavulinic acid photodynamic therapy for tumour-stage mycosis fungoides. Br J Dermatol 2001; 144: 1262-3.
4. Edström DW, Porwit A, Ross A. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: Clinical and histological response. Acta Derm Venereol 2001; 81: 184-8.
5. Fung MA, Murphy MJ, Hoss DM, Grant-Kels JM. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol 2002; 46: 325-57.
6. Stein H, Foss HD, Dürkop H et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000; 96: 3681-95.
7. Hampton JA, Selman SH. Mechanism of cell killing in photodynamic therapy using a novel in vivo drug/in vitro light culture system. Photochem Photobiol 1992; 56: 235-43.
8. Gibson SL, van der Meid KR, Murant RS, Hilf R. Increased efficacy of photodynamic therapy of R3230AC mammary adenocarcinoma by intratumoural injection of photofrin II. Br J Cancer 1990; 61: 553-7.
9. He X-Y, Sikes R, Thomsen S et al. Photodynamic therapy with photofrin II induces programmed cell death in carcinoma cell lines. Photochem Photobiol 1994; 59: 468-73.
10. Dellinger M. Apoptosis or necrosis following Photofrin photosensitization: influence of the incubation protocol. Photochem Photobiol 1996; 64: 182-7.
11. Levi E, Wang Z. Petrogiannis-Haliotis T et al. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression. J Invest Dermatol 2000; 115: 1034-40.